e-ISSN 1309-2545      ISSN 1301-062X
TR    ENG
 

Download Current Issue.

Volume : 28 Issue : 2 Year : 2022

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login Copyright Transfer Form
Turkish Journal of Neurology Indexed By
  lnterferon Beta-1b In TheTreatment Of Relapsing Remitting Multiple Sclerosis:Clinical and Magnetic Resonance lmaging Results [Turk J Neurol]
Turk J Neurol. 2001; 7(1): 27-38

lnterferon Beta-1b In TheTreatment Of Relapsing Remitting Multiple Sclerosis:Clinical and Magnetic Resonance lmaging Results

Serkan ÖZAKBAŞ1, Egemen İDİMAN1, Handan ÇAKMAKÇI2, İlhami KOVANLIKAYA2
1Dokuz Eylül Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı
2Dokuz Eylül Üniversitesi Tıp Fakültesi, Radyoloji Anabilim Dalı

Multiple Sclerosis (MS) is a chronic disease characterized wiyh glial scarring, demyelination and multiple white matter inflammation in central nervous system. There are strong evidence that MS is a autoimmune disease in this immun attack, it is suggested that target is myelin or oligodendrocyte. The inflammatory damage of myelin leads to appear the symptoms disturbing the nerve conduction. İn some clinicalstudies, it has been reported that interferon beta-1 b reduces the attack rate, slow down the disability and reduces the activity and number of lesions in magnetic resonance imaging (MRI). İn this study, 8 million unit interferon beta-1 b was given to 17 (2 male and 15 female) relapsingremitting MS patients who have at least 2 attacks in the last two years, short duration of disease, low Expanded Disability Status Scale (EDSS) scores,for 9 months subcutaneously. Clinical evaluation and MRI studies were performed before the treatment and in the 2nd, 4th, 6th and 9th months during the therapy. Clinical evaluation was performed on the base of EDSS. The mean age of the cases was 32.2±95.45 years, mean disease duration was 2.44±0.61 years, mean EDSS scoreat onset was 2.20±0.41, mean attack rate in the last two years 2.06±0. 90, mean MRI score (on the base of number of lesions) at onset was 45.76±29.09. EDSS score decreased significantly in 4th (p=0.0277), 6th (p=0.0015) and 9th months. MRI scores decreased in the 4th (p =0409), 6th (p =0.0019) and 9th (p =0007). Severe side effects are not seen during the treatment. İt is suggested that interferon beta-1 b has an effect on disability and decrease the MRI detected lesions in MS.

Keywords: Multiple Sclerosis, Magnetic Resonance lmaging, lnterferon Beta-1 b, EDSS


Serkan ÖZAKBAŞ, Egemen İDİMAN, Handan ÇAKMAKÇI, İlhami KOVANLIKAYA. lnterferon Beta-1b In TheTreatment Of Relapsing Remitting Multiple Sclerosis:Clinical and Magnetic Resonance lmaging Results. Turk J Neurol. 2001; 7(1): 27-38

Corresponding Author: Serkan ÖZAKBAŞ


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
© Copyright 2022 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale